202 related articles for article (PubMed ID: 23061485)
1. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Macdonald DA; Assouline SE; Brandwein J; Kamel-Reid S; Eisenhauer EA; Couban S; Caplan S; Foo A; Walsh W; Leber B
Leuk Lymphoma; 2013 Apr; 54(4):760-6. PubMed ID: 23061485
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Serve H; Krug U; Wagner R; Sauerland MC; Heinecke A; Brunnberg U; Schaich M; Ottmann O; Duyster J; Wandt H; Fischer T; Giagounidis A; Neubauer A; Reichle A; Aulitzky W; Noppeney R; Blau I; Kunzmann V; Stuhlmann R; Krämer A; Kreuzer KA; Brandts C; Steffen B; Thiede C; Müller-Tidow C; Ehninger G; Berdel WE
J Clin Oncol; 2013 Sep; 31(25):3110-8. PubMed ID: 23897964
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Ravandi F; Cortes JE; Jones D; Faderl S; Garcia-Manero G; Konopleva MY; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce SR; Brandt M; Byrd A; Bekele BN; Pratz K; Luthra R; Levis M; Andreeff M; Kantarjian HM
J Clin Oncol; 2010 Apr; 28(11):1856-62. PubMed ID: 20212254
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Fontanelli G; Rocco M; Caracciolo F; Benedetti E; Buda G; Orciuolo E; Carulli G; Galimberti S; Azzarà A; Petrini M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e13-7. PubMed ID: 24144836
[No Abstract] [Full Text] [Related]
6. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Al-Kali A; Cortes J; Faderl S; Jones D; Abril C; Pierce S; Brandt M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):361-6. PubMed ID: 21816375
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Giri S; Hamdeh S; Bhatt VR; Schwarz JK
J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Sid S; Rey J; Charbonnier A; D'Incan E; Mohty B; Blaise D; Vey N
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):241-242. PubMed ID: 28196687
[No Abstract] [Full Text] [Related]
12. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Guenounou S; Delabesse E; Récher C
Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
[TBL] [Abstract][Full Text] [Related]
14. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Liu XS; Long H; Huang YX; Xu JH; Zhu JY; DU QF; Wu BY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):394-8. PubMed ID: 27150998
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
Osone S; Imamura T; Kanayama T; Tsuma Y; Kawashima-Goto S; Nakatani T; Sugimoto A; Takai A; Miyachi M; Tamura S; Ishida H; Hosoi H
J Pediatr Hematol Oncol; 2017 May; 39(4):e199-e202. PubMed ID: 27571118
[TBL] [Abstract][Full Text] [Related]
17. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Ravandi F; Arana Yi C; Cortes JE; Levis M; Faderl S; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce S; Brandt M; Pratz K; Luthra R; Andreeff M; Kantarjian H
Leukemia; 2014 Jul; 28(7):1543-5. PubMed ID: 24487412
[No Abstract] [Full Text] [Related]
18. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
19. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
[TBL] [Abstract][Full Text] [Related]
20. Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.
Wei A; Tan P
Leuk Lymphoma; 2013 Apr; 54(4):675-6. PubMed ID: 22988956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
